Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
Histone deacetylases (HDACs) catalyze the removal of acetyl groups from histones and contribute to transcriptional repression. In addition, the HDAC inhibitors induce apoptosis in cancer cells through alterations in histone acetylation and activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) apoptotic pathway. Lysophosphatidic acid (LPA) is a growth factor that promotes survival of cancer cells through activation of G protein-coupled receptors. Here we show that HDAC inhibitors can induce apoptosis through activation of the TRAIL apoptotic pathway, and LPA prevented HDAC inhibitor-induced apoptosis and increased TRAIL receptor DR4 (death receptor 4) protein expression. This was associated with increased HDAC1 recruitment to the DR4 promoter following LPA treatment and a reduction in HDAC inhibitor-induced histone acetylation in the DR4 promoter. In addition, LPA induces HDAC enzyme activity in a dose- and time-dependent manner, and this is associated with HDAC1 activation and increased binding of HDAC1 to HDAC2. Reducing the expression of HDAC1 significantly lowered LPA-induced HDAC activity and increased histone acetylation. LPA induction of HDAC activity was blocked by the LPA receptor antagonist, Ki16425, or by inhibiting receptor activation with pertussis toxin. Reducing the expression of the LPA receptor LPA(1) also blocked LPA-induced HDAC activation. In addition, LPA reduced histone acetyltransferase enzymatic activity. Finally, LPA attenuated the ability of the HDAC inhibitor to reduce HDAC activity. Thus, LPA enhances survival of cancer cells by increasing HDAC activity and reducing histone acetylation.
Ishdorj
Ganchimeg
G
Manitoba Institute of Cell Biology, Winnipeg, Manitoba R3E 0V9, Canada.
Graham
Bonnie A
BA
Hu
Xiaojie
X
Chen
Jing
J
Johnston
James B
JB
Fang
Xianjun
X
Gibson
Spencer B
SB
D017209:Apoptosis; D002384:Catalysis; D002462:Cell Membrane / Q000378:metabolism; D056464:Histone Deacetylase 2; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006657:Histones / Q000737:chemistry; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D008214:Lymphocytes / Q000378:metabolism; D008246:Lysophospholipids / Q000494:pharmacology*; D008954:Models, Biological; D009369:Neoplasms / Q000201:enzymology* / Q000378:metabolism; D010539:Permeability; D011401:Promoter Regions, Genetic; D011422:Propionates / Q000494:pharmacology; D012097:Repressor Proteins / Q000378:metabolism
C477898:3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D007555:Isoxazoles; D008246:Lysophospholipids; D011422:Propionates; D012097:Repressor Proteins; D056464:Histone Deacetylase 2; D006655:Histone Deacetylases; C032881:lysophosphatidic acid